-
About
- Health
-
Patient Care
I Want To...
-
Research
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
-
School of Medicine
I Want to...
Past Event: Launching The Lancet Oncology Commission on Future Cancer Research Priorities in the USA
Immunotherapy: Precision Medicine in Action
The importance of keeping the promise and potential of immunotherapy alive
The first cancer immunotherapy was approved in 2011; today, there are more than 70 such drugs in the clinical pipeline. By 2020, the cancer treatment industry is expected to achieve $16.55 billion dollars in revenue. Read our policy brief to learn more about milestones in cancer immunotherapy.
2011
70
$16.55
Hear from top scientists on how they recommend expanding and implementing the Blue Ribbon Panel’s road map for cancer research. They’ll discuss a report that will be published by the journal The Lancet Oncology and is co-edited by Elizabeth Jaffee, M.D., deputy director of the Johns Hopkins Kimmel Cancer Center, and Chi Van Dang, M.D., Ph.D., scientific director at Ludwig Cancer Research and professor at The Wistar Institute. Learn what you need to know about investing in research, prevention and treatment of cancer, the second leading cause of death in the U.S. Reserve your attendance now by emailing JHontheRoad@jhmi.edu.
Wednesday, November 1, from 8:30 a.m. to 12:00 p.m.
Capitol Hill Hart Senate Office Building, Room 902
120 Constitution Avenue NE, Washington, D.C. 20002
Speakers
Paul Rothman, M.D.
Dean of the Medical Faculty
CEO, Johns Hopkins Medicine
David Collingridge, Ph.D.
Editor-in-Chief, The Lancet Oncology
Elizabeth Jaffee, M.D.
Professor of Oncology and Deputy Director, Johns Hopkins Sidney Kimmel Cancer Center
Associate Director, Bloomberg-Kimmel Institute for Cancer Immunotherapy
Chi Van Dang, M.D., Ph.D.
Scientific Director, Ludwig Institute for Cancer Research
Professor, The Wistar Institute
Scott Lippman, M.D.
Professor of Medicine, Senior Associate Dean and Associate Vice Chancellor for Cancer Research and Care, University of California, San Diego
Jeffrey Peppercorn, M.D., M.P.H.
Director, Cancer Survivorship Program, Massachusetts General Hospital
Associate Professor of Medicine at Harvard Medical School
Cliff Hudis, M.D., F.A.C.P.
Chief Executive Officer of the American Society of Clinical Oncology
Douglas Lowry, M.D.
Deputy Director, National Cancer Institute
Sign Up for Fundamentals
Stay up-to-date with the latest research findings from the Institute for Basic Biomedical Sciences.